The National Heart, Lung, and Blood Institute (NHLBI) awarded a 5-year, $1,584,184 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center to develop deep learning algorithms that can precisely characterize mitral valve disease and identify accelerated cardiovascular risk trajectories. The researchers will leverage echocardiography data from both healthcare and community-based cohorts to train and validate AI models that can automate the phenotyping of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $791,113 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center. The grant, entitled "Artificial Intelligence Imaging Biomarkers of Longitudinal Cardiovascular Stress," will leverage advanced artificial intelligence (AI) techniques applied to echocardiography imaging data to predict biological cardiovascular age and identify contributors to accelerated versus delayed cardiovascular...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The 4-year grant, effective July 15, 2024 through June 30, 2028, will fund research to:
Identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol and blood pressure. This will involve conducting...
This $735,346 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund the development of an AI-powered, equitable, interpretable, and generalizable cardiovascular disease (CVD) risk prediction model. The primary awardee is the University of Massachusetts Medical School, which will partner with community health centers and academic hospitals to integrate clinical factors and multi-domain social...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $810,650 to Cedars-Sinai Medical Center to develop and validate an artificial intelligence (AI)-enabled algorithm for automated quantification of fibrotic and calcific aortic valve tissue characteristics from standard computed tomography angiography (CTA). The goal is to predict rapid aortic valve disease progression and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will develop, validate, and determine the clinical utility of a precision genetic testing approach guided by machine learning algorithms. The $756,895 award to Duke University, with sub-awards to Mayo Clinic and the Medical University of South Carolina, aims to enhance the diagnosis of two monogenic cardiovascular disorders: hypertrophic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $173,609 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Washington University to develop and evaluate a personalized, AI-based clinical decision support (CDS) system to guide presurgical blood orders and improve perioperative blood management. The project aims to assess the feasibility and preliminary effectiveness of the S-PATH CDS tool, which estimates surgical transfusion risk, when embedded within the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $126,750.00 to the Icahn School of Medicine at Mount Sinai (ISMMS) to validate a novel clinical trial endpoint for evaluating acute graft-versus-host disease (GVHD) outcomes. The research aims to demonstrate that a day 14 MAGIC (Mount Sinai Acute GVHD International Consortium) integrated response model, which incorporates both...
This Federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is supporting research to leverage large-scale biobanks to discover and define rare genetic variant effects on hypertrophic cardiomyopathy (HCM). The $767,579 award to Vanderbilt University Medical Center (VUMC) aims to address key knowledge gaps by: 1) defining the contribution and phenotypic manifestations of established HCM disease...
The Department of Health and Human Services' National Heart, Lung, and Blood Institute (NHLBI) awarded a $515,160 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, active from April 15, 2024 to March 31, 2029, will support research to understand the role of DNA methyltransferase 3A (DNMT3A) in regulating graft-versus-host disease (GVHD) and the graft-versus-tumor (GVT) effect in allogeneic hematopoietic cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $3,181,696 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Vanderbilt University Medical Center (VUMC) to validate an artificial intelligence (AI) technology for accurately measuring skin erythema, a key biomarker of chronic graft-versus-host disease (cGVHD), from patient photographs. The 5-year project will leverage a unique database of over 11,000 photographs and clinical information from diverse cGVHD patients across five major cancer centers to develop and validate the AI tool. The project aims to enable consistent cGVHD scoring equivalent to specialist examinations, improve telemedicine monitoring, and reduce the burden on healthcare providers. VUMC will collaborate with subrecipients including Mayo Clinic, Fred Hutchinson Cancer Center, and the University of Pennsylvania on this multi-site effort to advance the diagnosis and management of this serious post-transplant complication.